" "
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SYGNIS Licenses Amplification Buffer to QIAGEN

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
This is the second agreement with QIAGEN within 9 months.

Spanish-German biotech company SYGNIS Pharma AG has signed a licence agreement for the distribution of a new amplification buffer with QIAGEN. This is the first licence agreement for the amplification buffer technology developed by the team led by renowned Professor Margarita Salas at the CSIC laboratory.

The recently granted licence covers a new amplification buffer, a tool used in isothermal amplification, providing superior reaction performance.

“With the new agreement, SYGNIS adds a global reference in the sector in the fields of DNA amplification research and commercial markets. This newly signed agreement shows that SYGNIS is making progress in the commercialization of core technologies and products designed for the DNA sequencing and amplification market. It strengthens the network of relationships we maintain with life science and diagnostics companies in the DNA amplification industry,” SYGNIS’ CEO Pilar de la Huerta commented.

Background

In July 2012, through X-POL, SYGNIS reached an exclusive global licence agreement with QIAGEN for the distribution of the polymerase QualiPhi®.

QualiIPhi® is an upgraded version of phi 29 DNA polymerase. Compared to similar polymerase proteins on the market, the new one exhibits enhanced properties. Being less time-consuming and having highly superior performance characteristics, the method developed by SYGNIS enables DNA amplification from concentrations as low as those found in a single cell. This is extremely useful in cancer research, among other applications.

Polymerase proteins are the main tool for amplifying long DNA fragments and whole genomes, and are basic in research involving analysis and modification of DNA from any species.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS Reports Financial Results for Fiscal Year 2014
Successful change in product and commercialization strategy with strong focus on proprietary product portfolio.
Saturday, May 09, 2015
SYGNIS Signs Non-exclusive Distribution Agreement with Cambridge Bioscience
Significant expansion of product roll-out into one of the most important life science markets in Europe.
Tuesday, May 05, 2015
SYGNIS Signs Non-Exclusive Distribution Agreement with SOPACHEM
SOPACHEM is a specialized distributor with focus on life sciences, diagnostics, biobanking and analytical applications.
Thursday, March 19, 2015
SYGNIS Reports Financial Results for Fiscal Year 2012
Strategic realignment completed - discontinuation of drug development.
Wednesday, May 01, 2013
Scientific News
‘Smelling’ Prostate Cancer
A research team from the University of Liverpool and the University of the West of England (UWE Bristol) has reached an important milestone towards creating a urine diagnostic test for prostate cancer that could mean that invasive diagnostic procedures that men currently undergo eventually become a thing of the past.
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!